论文部分内容阅读
今年以来,国家继续采取适当的宏观调控措施,改革力度进一步深化,整个经济运行环境趋紧。然而,全国医药工商企业在资金继续紧张,原辅材料及能源价格持续上涨的情况下,克服困难,保持着良好的发展势头,从整体上看,呈现出产销两旺,市场活跃的局面。据资料统计,1994年上半年医药工业企业完成产值383.68亿元,同比增长32.66%;产品销售收入318.47亿元,同比增长30.12%;实现利税34.65亿元,同比增长19.32%,其中利润增长38.75%;销售利润率为5.19%,同比增长0.32个百分点;资产负债率为73.29%,同比增加0.95个百分点;亏损户数为833户,亏损面
Since the beginning of this year, the country has continued to adopt appropriate macro-control measures, further deepening reforms and tightening the entire economic operating environment. However, as the nation’s pharmaceutical and industrial and commercial enterprises continue to be under strained funding, and raw and auxiliary materials and energy prices continue to rise, they have overcome difficulties and maintained a good momentum of development. On the whole, they have seen a boom in production and sales, and an active market. According to statistics, in the first half of 1994, the pharmaceutical industry completed a production value of 38.368 billion yuan, a year-on-year increase of 32.66%; the product sales revenue was 31.847 billion yuan, an increase of 30.12% year-on-year; the profits and taxes were 3.465 billion yuan, a year-on-year increase of 19.32%, of which the profit growth was 38.75%. The sales profit rate was 5.19%, an increase of 0.32 percentage points over the same period of last year; the asset-liability ratio was 73.29%, an increase of 0.95 percentage points over the same period of last year; the number of loss households was 833, the loss surface